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Background
Recently, MP29-02* (a novel intranasal formulation of
azelastine hydrochloride [AZ] and fluticasone propionate
[FP]) has demonstrated significant clinical effects in AR
compared to these drugs in monotherapy. The aim of
this study was to investigate the anti-inflammatory effect
of MP29-02* compared to AZ and FP alone in an in
vitro validated model of eosinophilic inflammation.
Methods
Peripheral blood eosinophils were incubated for 4 days
with decreasing dilutions of MP29-02* (from 1:102 to
1:105 times), equivalent dilutions of FP (7.3x10-6M to
10-9M) or AZ (2.4x10-5M to 10-8M) prior to the addi-
tion of Epithelial Cell culture Media (ECM) from nasal
mucosa (NM). Eosinophil survival was assessed by
Trypan blue dye exclusion. Results are expressed as per-
centage (mean ± SEM) of eosinophil survival compared
to control (100%).
Results
ECM from NM at 10% induced eosinophil survival from
day 1 to 4. This effect was inhibited in a dose-response
manner by MP29-02* and FP alone (from day 2 to 4) and
AZ alone (only at day 4). At day 3, MP29-02* signifi-
cantly inhibited eosinophil survival induced by ECM
from dilution 1:102 (13.8±1.5%, N=6) to dilution 1:105
(58.8±10.8%, N=6), compared to ECM (100%). This inhi-
bitory effect on eosinophil survival induced by MP29-02*
at 1:102 dilution (13.8±1.5%) was significantly (p<0.05)
stronger than that induced by FP alone (36.7±6.3) or AZ
alone (70.3±10.4%) at similar dilutions.
Conclusions
These results suggest that MP29-02* may reduce upper
airway eosinophilic infiltration more potently than corti-
costeroids or antihistamines administered alone. This
anti-inflammatory effect may account, at least in part,
for the stronger clinical effect of MP29-02* on moderate
to severe allergic rhinitis when compared to these drugs
in monotherapy.
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